A genetic flaw becomes a lethal vulnerability for cancer cells
In short: Your body is constantly repairing its own DNA, a process managed by the BRCA2 gene on chromosome 13. While a mutation in this gene can lead to cancer, it also creates a unique molecular weakness. Scientists are now weaponizing this specific defect to kill tumors from the inside out.
The BRCA2 gene is essential for maintaining genomic integrity. It encodes a large protein responsible for repairing DNA damage caused by everyday biological processes, as well as external factors like tobacco smoke and UV radiation. When BRCA2 functions correctly, it ensures that the 'recipe' of our DNA remains intact. However, when germline mutations occur in BRCA1 or BRCA2, the body loses its ability to perform precise DNA repair via a process called homologous recombination. Such conditions provoke genomic instability, causing an accumulation of DNA damage that ultimately converts normal, non-tumorigenic cells into cancer stem cells (CSCs) or tumor-initiating cells.
These mutations are associated with approximately 20% of familial breast and ovarian cancers. While the link to gynecological cancers is strong, the contribution of BRCA mutations to hereditary pancreatic, stomach, and prostate cancers is considered marginal. Despite these differences, the underlying mechanism remains the same: the loss of BRCA function acts as an engine for oncogenic transformation. Cancer cells born from these mutations are particularly dangerous because they can develop into cancer stem cells, which possess the long-term self-renewal capacity to drive tumor evolution and progression.
The breakthrough in treatment lies in a concept called synthetic lethality. Because cancer cells with a faulty BRCA2 gene lack their primary repair tool, they become entirely dependent on a backup system involving another gene called PARP. This creates a strategic opportunity for clinicians. By using drugs known as PARP inhibitors to block this secondary repair pathway, scientists can prevent cancer cells from fixing their own DNA. While healthy cells with functional BRCA2 genes can survive this blockade, the cancer cells are unable to repair themselves and eventually die off. This targeted approach is already showing great promise in clinical trials.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Chromosome 13 - BRCA2 and DNA Damage
- Also: BRCA Genes: The Role in Genome Stability, Cancer Stemness and Therapy Resistance
To cite this card, link to https://intellectplus.co.uk/app/ideas-chromosome-13-brca2-and-dna-damage.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
